Sugi Predict

Sugi Predict / Targets / KCNQ3

KCNQ3

Potassium voltage-gated channel subfamily KQT member 3 · O43525 · KCNQ3 on Sugi Atlas →

33,267 patent compounds predicted against KCNQ3, 16,071 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL774698 SCHEMBL774698 0.77 20/20
SCHEMBL367538 SCHEMBL367538 1.00 19/20
SCHEMBL321477 SCHEMBL321477 1.00 17/20
SCHEMBL265831 SCHEMBL265831 0.72 16/20
SCHEMBL401818 SCHEMBL401818 0.71 16/20
SCHEMBL203109 SCHEMBL203109 0.54 15/20
SCHEMBL9148 SCHEMBL9148 0.55 13/20
SCHEMBL774620 SCHEMBL774620 0.59 12/20
SCHEMBL535403 SCHEMBL535403 0.53 12/20
SCHEMBL401850 SCHEMBL401850 0.64 11/20
SCHEMBL403408 SCHEMBL403408 0.72 10/20
SCHEMBL403003 SCHEMBL403003 0.68 10/20
SCHEMBL954966 SCHEMBL954966 0.48 9/20
Flupirtine Flupirtine (SCHEMBL505322) 0.86 8/20
Flupirtine Flupirtine (SCHEMBL505880) 0.80 8/20
Flupirtine Flupirtine (SCHEMBL505354) 0.74 8/20
SCHEMBL403184 SCHEMBL403184 0.67 8/20
SCHEMBL404209 SCHEMBL404209 0.57 8/20
SCHEMBL320941 SCHEMBL320941 0.52 8/20
SCHEMBL322079 SCHEMBL322079 0.50 8/20

Clinical trials — most relevant to KCNQ3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Study to Treat Major Depressive Disorder With a New Medication PHASE2COMPLETED
Long QT Syndrome Screening in Newborns PHASE2UNKNOWN
A Study of JMT203 in Patients With Cancer Cachexia PHASE1/PHASE2RECRUITING
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss PHASE2COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet PHASE1NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome nanCOMPLETED
Na+ Channel mRNA Regulation in Heart Failure nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Prospective Identification of Long QT Syndrome in Fetal Life nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
A Positional Cloning Study on Schizophrenia nanCOMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients nanUNKNOWN
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies nanUNKNOWN
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNQ3 binder may also engage these)

ProteinNameSimilarity
O88944 — 1.000 O88944 →
Q8K3F6 — 1.000 Q8K3F6 →
P58126 — 1.000 P58126 →
Q9Z351 — 1.000 Q9Z351 →
O88943 — 1.000 O88943 →
KCNQ5 Potassium voltage-gated channel subfamily KQT member 5 0.999 landscape →
KCNQ2 Potassium voltage-gated channel subfamily KQT member 2 0.998 landscape →
P97414 — 0.998 P97414 →
O97531 — 0.995 O97531 →
Q9TTJ7 — 0.994 Q9TTJ7 →
Q9Z0N7 — 0.994 Q9Z0N7 →
Q9JK97 — 0.993 Q9JK97 →
Q9JK45 — 0.993 Q9JK45 →
KCNQ4 Potassium voltage-gated channel subfamily KQT member 4 0.993 landscape →
Q9MYS6 — 0.991 Q9MYS6 →
O70344 — 0.990 O70344 →
Q9JK96 — 0.990 Q9JK96 →
Q9TUI4 — 0.989 Q9TUI4 →
KCNQ1 Potassium voltage-gated channel subfamily KQT member 1 0.988 landscape →
Q5JCS6 — 0.987 Q5JCS6 →
O73925 — 0.987 O73925 →
A2AHC3 — 0.987 A2AHC3 →
Q60603 — 0.986 Q60603 →
Q62968 — 0.986 Q62968 →
Q76LL6 — 0.986 Q76LL6 →
Q9D3S3 — 0.986 Q9D3S3 →
P15389 — 0.985 P15389 →
Q8NDI1 — 0.985 Q8NDI1 →
Q3UMB5 — 0.985 Q3UMB5 →
O60292 — 0.985 O60292 →